CD4 and gastric cancer: The pre-treatment CD4+/CD8+ TILs ratio by immunohistochemistry on gastric cancer tissues revealed a remarkable correlation with lymphovascular invasion, TNM stage and response to neoadjuvant chemotherapy, and lower CD4+/CD8+ TILs ratio predicted significantly better survival outcomes [36].